Detalhe da pesquisa
1.
Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.
Mol Carcinog
; 62(11): 1717-1730, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37493106
2.
Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Mol Carcinog
; 58(10): 1770-1782, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31219654
3.
Depletion of the Insulator Protein CTCF Results in Herpes Simplex Virus 1 Reactivation In Vivo.
J Virol
; 92(11)2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29514910
4.
In Vivo Knockdown of the Herpes Simplex Virus 1 Latency-Associated Transcript Reduces Reactivation from Latency.
J Virol
; 92(16)2018 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29875240
5.
Adeno-associated Virus Vectors Efficiently Transduce Mouse and Rabbit Sensory Neurons Coinfected with Herpes Simplex Virus 1 following Peripheral Inoculation.
J Virol
; 90(17): 7894-901, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27334582
6.
PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
Gynecol Oncol
; 147(3): 695-704, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29037806
7.
CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR.
Cancer Gene Ther
; 31(2): 300-310, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030811
8.
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Mol Cancer Ther
; : OF1-OF16, 2024 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38863225
9.
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Mol Cancer Ther
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38714351
10.
Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer.
bioRxiv
; 2023 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37066339
11.
Novel chromobox 2 inhibitory peptide decreases tumor progression.
Expert Opin Ther Targets
; 27(4-5): 361-371, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243607
12.
Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models.
bioRxiv
; 2023 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36865165
13.
Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression.
Mol Cancer Res
; 18(7): 1088-1098, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198139
14.
The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval.
Clin Cancer Res
; 26(23): 6362-6373, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32928797
15.
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
Mol Cancer Ther
; 19(2): 602-613, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31575654
16.
A limited innate immune response is induced by a replication-defective herpes simplex virus vector following delivery to the murine central nervous system.
J Neurovirol
; 15(5-6): 411-24, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20095947
17.
Type I Protein Arginine Methyltransferases Overexpression Promotes Transformation and Potentiates Her2/Neu-Driven Tumorigenesis.
Cancer Res
; 79(1): 3-4, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30602621
18.
Peripheral AAV Injection for Retrograde Transduction of Dorsal Root and Trigeminal Ganglia.
Methods Mol Biol
; 1950: 237-247, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30783977
19.
Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Clin Epigenetics
; 11(1): 165, 2019 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31775874
20.
Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination.
iScience
; 19: 474-491, 2019 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31437751